bioAffinity Technologies Inc. (NASDAQ:BIAF) saw its stock climb to $2.96 during pre-market trading on Wednesday, marking a 20.82% jump from its previous close. The surge came after the company released its third-quarter sales update.

Check out the current price of BIAF stock here

Third Quarter Sales Performance

The Texas-based company announced on Tuesday that sales of its CyPath® Lung diagnostic test reached a record high in the third quarter, marking a 95% increase from the previous quarter. For the first nine months of 2025, sales rose 97% compared to the same period last year.

Test Specifications

The test uses advanced technology to examine mucus …

Full story available on Benzinga.com